Effectiveness,safety and tolerability of codeine in cancer patients

• DOI: 10.1200/jco.2006.24.18_suppl.18577
• Publication Date: 2020-04-17T13:29:56Z
• Authors: G. L. Moura; M. Giublin; L. Albini; R. Pasquini; K. Viana; F. Chicoski
• Keywords: Tolerability

18577 Background: In 1984 WHO guidelines for cancer pain was proposed. Codeine selected among several others drugs when ladder step II required. Since then very few comparative studies have been performed. Codein is a weak opioid and its analgesic action not completely understood. A possible conversion into morphine postulated. To determine efficacy, safety tolerability of codein in advanced patient we designed prospective cohort study. Methods 150 metastatic patients were studied during six months. standard zero to table scale rating used. The malignacies were: prostate 15 (10%), breast 42 (28%), lung 33 (22%), colon 37 (24.6%), other 23 (15.3%). 62 under treatment (41.3%). Results: There 83 M (55.3%) 67 F(44,7%) the mean age years. Mean initial final score 7.1 1.3 respectively. dose range from 30 mg/day 270 (mean 180 mg/day). average time use 13,7 Severe toxicity 0% most often side effect constipation (38.7%). Adjuvant used 97 (64.7%) patients. Uncontrolled ocurred 17 (11.3%). Conclusions: During last decade great increase agents formulations available emerged. still represents an excellent drug with long life expectancy. Side effects are manageable mainly constipation. Pain control achieved majority showed low profile high compliance rate. Economic reasons must be strongly consider poor countries good alternative option. Future addressing also quality should No significant financial relationships disclose.